Investment Thesis
Journey Medical exhibits deteriorating fundamentals with negative operating margins (-9.3%), inability to cover interest expenses from operations (coverage ratio -1.7x), and unsustainable free cash flow burn (-$12.1M) on minimal revenue growth (+1% YoY). Despite adequate liquidity ($27.2M cash), the current burn rate provides approximately 2 years of runway, and without significant operational improvements or revenue acceleration, the company faces material financing risk.
Strengths
- Positive operating cash flow of $2.9M demonstrates some operational traction and revenue collection
- Strong liquidity position with current ratio of 1.72x and quick ratio of 1.47x providing near-term financial flexibility
- Reasonable leverage with debt/equity ratio of 0.82x and $27.2M cash reserves reducing immediate solvency risk
Risks
- Unprofitable operations with -$1.5M operating loss and -14.0% net margin on flat revenue growth indicates core business model is not generating value
- Cannot service debt from operations (interest coverage ratio -1.7x), forcing reliance on cash reserves for interest payments; unsustainable long-term
- Free cash flow burn of -$12.1M annually combined with $15.0M capex indicates unsustainable cash consumption with finite runway absent major revenue inflection or funding
Key Metrics to Watch
- Revenue growth acceleration and path to profitability (operating margin must turn positive)
- Free cash flow and interest coverage ratio trends (negative coverage is critical red flag)
- Cash burn rate and remaining runway; monitor for covenant violations on $25.4M long-term debt
Financial Metrics
Revenue
16.0M
Net Income
-2.2M
EPS (Diluted)
$-0.08
Free Cash Flow
-12.1M
Total Assets
91.5M
Cash
27.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-9.3%
Net Margin
-14.0%
ROE
-7.2%
ROA
-2.4%
FCF Margin
-75.8%
Balance Sheet & Liquidity
Current Ratio
1.72x
Quick Ratio
1.47x
Debt/Equity
0.82x
Debt/Assets
66.3%
Interest Coverage
-1.67x
Long-term Debt
25.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:06:23.367544 |
Data as of: 2026-03-31 |
Powered by Claude AI